[Ip-health] webinar Apr 25 - Public funding of drug development: contributions of the US NIH

marcela vieira marcelacfvieira at gmail.com
Mon Apr 15 07:26:01 PDT 2019


Dear ip-health readers,
We are pleased to invite you to the next webinar organized by the Knowledge
Network on Innovation and Access to Medicines, presenting recent research
and analysis on topics relating to pharmaceuticals policy. We hope it is of
interest to people on this list.

*Public funding of drug development: contributions of the US NIH*
Thursday 25 April | 4:00pm-5:00pm CEST | 10:00am-11:00am EDT

To join the webinar, please register here
<https://zoom.us/webinar/register/9115553366884/WN_5bjfqPfDTSugX0KvHs9ATw>.

*Speaker:*
Dr. Ekaterina Cleary, Lead Data Analyst and Adjunct Professor at the Center
for Integration of Science and Industry, Bentley University.

*Paper:*
"Contribution of NIH funding to new drug approvals 2010–2016”
<https://www.pnas.org/content/115/10/2329.long>
Ekaterina Galkina Cleary, Jennifer M. Beierlein, Navleen Surjit Khanuja,
Laura M. McNamee, and Fred D. Ledley

The process to develop new medicines can be long, costly and complex, and
involve many different actors from the private, public and non-profit
sectors. While the role of the private sector is widely-recognized, there
has generally been less data and understanding of the role of public and
non-profit actors. A number of recent studies have documented the
contributions of public actors across all phases of the drug research and
development process.

Lead author Dr. Ekaterina Cleary will present a recently-published study
(above) examining US National Institutes of Health (NIH) funding associated
with 210 new molecular entities (NMEs) approved by the US Food and Drug
Administration (FDA) from 2010–2016. The study found that NIH funding
contributed to both basic and applied research associated with every one of
these medicines. Dr. Cleary will explain the methodology her team used to
find and analyze the relevant data, including the NIH RePORTER tool. The
conclusion suggests that the NIH contribution to drug development is
greater than previously appreciated.

To join the webinar, please refer to further instructions sent in the
confirmation e-mail after the registration has been completed using the
link above.

This event is part of the webinar series of the Knowledge Network for
Innovation and Access to Medicines, a project of the Global Health Centre
at the Graduate Institute of Geneva. Suggestions for speakers and topics
for future webinars are welcome at globalhealthresearch at graduateinstitute.ch
.

---
Marcela Vieira
Project Coordinator
Knowledge Network for Innovation and Access to Medicines
Global Health Centre, Research
Graduate Institute of International and Development Studies
marcela.vieira at graduateinstitute.ch


More information about the Ip-health mailing list